Skip to main content
Journal cover image

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Publication ,  Journal Article
Butler, J; Hamo, CE; Filippatos, G; Pocock, SJ; Bernstein, RA; Brueckmann, M; Cheung, AK; George, JT; Green, JB; Januzzi, JL; Kaul, S; Marx, N ...
Published in: Eur J Heart Fail
November 2017

Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. Several anti-hyperglycaemic medications have been associated with a concern for worse HF outcomes. More recently, the results of the EMPA-REG OUTCOME trial showed that the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was associated with a pronounced and precocious 38% reduction in cardiovascular mortality in subjects with T2DM and established cardiovascular disease [Correction added on 8 September 2017, after first online publication: "32%" in the previous sentence was corrected to "38%"]. These benefits were more related to a reduction in incident HF events rather than to ischaemic vascular endpoints. Several mechanisms have been put forward to explain these benefits, which also raise the possibility of using these drugs as therapies not only in the prevention of HF, but also for the treatment of patients with established HF regardless of the presence or absence of diabetes. Several large trials are currently exploring this postulate.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

November 2017

Volume

19

Issue

11

Start / End Page

1390 / 1400

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium-Glucose Transporter 2
  • Sodium
  • Hypoglycemic Agents
  • Humans
  • Heart Failure
  • Glucosides
  • Cardiovascular System & Hematology
  • Benzhydryl Compounds
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., … EMPEROR Trials Program, . (2017). The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail, 19(11), 1390–1400. https://doi.org/10.1002/ejhf.933
Butler, Javed, Carine E. Hamo, Gerasimos Filippatos, Stuart J. Pocock, Richard A. Bernstein, Martina Brueckmann, Alfred K. Cheung, et al. “The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.Eur J Heart Fail 19, no. 11 (November 2017): 1390–1400. https://doi.org/10.1002/ejhf.933.
Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017 Nov;19(11):1390–400.
Butler, Javed, et al. “The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.Eur J Heart Fail, vol. 19, no. 11, Nov. 2017, pp. 1390–400. Pubmed, doi:10.1002/ejhf.933.
Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle H-J, Zannad F, Anker SD, EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017 Nov;19(11):1390–1400.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

November 2017

Volume

19

Issue

11

Start / End Page

1390 / 1400

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium-Glucose Transporter 2
  • Sodium
  • Hypoglycemic Agents
  • Humans
  • Heart Failure
  • Glucosides
  • Cardiovascular System & Hematology
  • Benzhydryl Compounds